We only have this paper's title and publication details.
Read it at the sourcePatients would be safer if drug companies disclosed adverse events before licensing
No takes yet. Share an insight, caveat, or question.
Dieppe et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: